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The pathways between basic science, clinical practice and health outcomes are 
multifaceted and complex. Analysis of these pathways has attracted the interest of the 
biomedical research community and public health agencies. Researchers and funding 
agencies are concerned with the ways in which scientific breakthroughs and evidence-based 
clinical findings are converted into practices with beneficial health impacts, including, but not 
limited to, therapies and medical guidelines. This interest is driven largely by the perception 
that many promising results from basic biomedicine have not contributed systematically to 
medical treatments and, ultimately, health care improvements.1 In response, a wide range of 
publicly-funded initiatives have been set up to address this problem. As the main aim of these 
initiatives is to facilitate the “translation” of scientific discoveries into beneficial applications 
and practices, many of these initiatives have been branded “Translational Research” (TR).  
TR has become a very popular term and has been applied to large research programmes, 
research activities and, even, academic journals, and has attracted the interest of biomedical 
scholars and institutions (Marincola 2003; Woolf 2008; Zerhouni 2007). The origins of the 
concept can be traced back to the 1990s, when the US National Cancer Institute (NCI) 
developed the Specialized Programs of Research Excellence (SPORE) (Lander and Atkinson-
Grosjean 2011). Starting in 1992, SPORE provided support for efforts to facilitate the 
“translation” of basic discoveries generated at academic centres, into new interventions aimed 
at preventing and treating various types of cancer. Since then, several policy initiatives have 
focused on the transformation of basic knowledge into health benefits. In the US, the 
                                                          
1 Some analysts estimate that less than 10% of the most promising biomedical discoveries resulted in any 
benefit to clinical practice two decades later (D.G. Contopoulos-Ioannidis, E.E. Ntzani, and J.P.A. Ioannidis, 
'Translation of Highly Promising Basic Science Research into Clinical Applications', The American Journal of 
Medicine, 114/6 (2003), 477-84; J. Ioannidis, 'Materializing Research Promises: Opportunities, Priorities and 
Conflicts in Translational Medicine', Journal of Translational Medicine, 2/1 (2004), 5.) 
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National Institutes of Health (NIH) launched the Roadmap Initiative (Zerhouni 2003), the 
Clinical and Translational Science Awards (Heller and de Melo-Martín 2009), and, in 
December 2011, a $575 million National Center for Advancing Translational Sciences 
(NCATS).2 TR initiatives have also been launched in the European Union and its Member 
States. Some are explicitly labelled TR programmes, others have similar objectives and 
rationales although they are labelled differently. For example, in 2006 the Spanish Ministry 
of Health launched the Networked Centres of Biomedical Research (CIBER)3 together with 
other research initiatives to facilitate the relationship between basic scientists and healthcare 
practitioners (Rey-Rocha and Martín-Sempere 2012). 
Often the more popular the policy concept, the more ambiguous it becomes. This clearly 
applies to TR and there is emerging debate on the models of research which are considered to 
be “translational” and the nature and characteristics of a putative TR discipline (Littman et al. 
2004). Consequently, the ways in which TR should be analysed, and more specifically the 
approaches to the evaluation of TR programmes are similarly open to debate. Given the 
substantial investment in TR programmes, the definition of TR evaluation strategies has 
become important for policy definition and implementation. Given the ambiguity about the 
type of activities that can be considered TR, evaluation approaches and practices can play an 
important role in determining these activities thus shaping the nature of TR initiatives. This 
paper discusses the dominant approaches to TR evaluation and proposes an alternative 
evaluation framework, which may have implications for the way in which TR programmes 
may be defined in the future.  
                                                          
2 www.ncats.nih.gov  





First, we provide an overview of the different ways in which TR is conceptualised. Many 
approaches consider TR as activities that bridge gaps in a continuum stretching from basic 
research to health outcomes (Morris et al. 2011). Other views emphasize the research process, 
how different groups interact, and how their roles may be redefined by a TR initiative (Currie 
and White 2012).  
Second, we discuss different evaluation approaches associated with these different views 
of TR. One of the dominant approaches focuses on the outputs generated at different points of 
the “translational research continuum” and estimates the time it takes to produce them. A 
focus on “what” and “when” implies a TR evaluation approach that attempts to identify 
results and how they differ from what would have been achieved in the absence of the 
initiatives being assessed. It should be emphasised that this focus on outputs may derive from 
an explicit view of TR as addressing “translational gaps” along a “TR continuum”, or may 
emerge without any explicit “theory” of the processes and objectives of TR. TR then is 
measured against success criteria based on the generation of outputs that are no different from 
the outputs generated by traditional research. Note that, in the absence of a “programme 
theory” the objectives of TR will, de facto, be defined by the evaluation strategy chosen. 
Our proposal is to focus, instead, on “how” research is carried out, on the processes of 
collaboration and exchange that can be attributed to TR initiatives. To this end, we develop 
an alternative TR evaluation framework that focuses on understanding the processes of 
change across the divides that hinder the application of the capabilities and knowledge 
generated by basic biomedicine to health care. The extant literature attributes the low level of 
practical application of biomedical research to a variety of causes, including: (i) the divide 
between the interests and skills of the different professional communities and disciplines, 
such as basic scientists, clinical scientists and clinical practitioners (Currie and White 2012); 
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(ii) the problem of communication among fields that are becoming more complex and 
specialised (Littman et al. 2004); and (iii) the existence of institutional barriers and 
occupational boundaries that hinder the effective flow of knowledge and interests (Lander 
and Atkinson-Grosjean 2011). 
Third, following the conceptual framework proposed by Ron Boschma (2005) we suggest 
that TR initiatives can operate by generating “proximities” along five different analytical 
dimensions: cognitive, social, organisational, institutional and geographical. We define these 
dimensions and argue that a TR support activity can be defined by the type of proximity it 
targets. We illustrate this by referring to two Spanish biomedical research programmes, and 
conclude by exploring the implications of using this alternative way of framing TR 
evaluation.  
TRANSLATIONAL RESEARCH: A VARIETY OF APPROACHES  
The development of TR initiatives reflects the perceived need to increase the chances that 
scientific discoveries will lead to benefits for patients, and to improve the alignment between 
biomedical research in biomedicine and health needs. TR emerged at a time when other 
initiatives aimed at facilitating the “valorization” or uptake of research by socio-economic 
actors were flourishing (Bozeman and Boardman 2004). TR has become part of the policy 
discourse justifying many current research funding programmes. The inclusion of the TR 
discourse in the policy agenda has been accompanied by intense academic discussion among 
biomedical scholars. What policy or management measures are needed to speed up the 
process of application of biomedical research advances to clinical practice? How should we 
characterize TR and evaluate TR initiatives? The development of a conceptual framework to 
describe the TR process and evaluate TR initiatives has become a theme in the academic 
research literature (for a review of the discussion see Drolet and Lorenzi, 2011).  
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The linear model of TR 
The most popular representations of TR assume a linear model of innovation (Rogers 
2003), prioritizing basic research as the primary source of new discoveries, which 
subsequently are developed into therapeutic solutions and finally are diffused to patients and 
the wider society. In the medical field, the adoption of this approach sees basic scientists at 
the origin of the innovation process, producing a large amount of fundamental knowledge at 
the molecular or cell level, some of which will be relevant for the development of new drugs 
or therapies. The fundamental knowledge generated by basic scientists moves forward 
through the stages of a “translational continuum” until eventually it is translated into specific 
benefits for patients or the general population, in the form of new drugs, devices and new 
prevention and treatment options. Every step in this linear progression addresses a specific 
problem and is undertaken by a specialized group of researchers. In this view, the successful 
application of new knowledge is dependent on the successful completion of every one of the 
stages along the “translational continuum” (Van der Laan and Boenink 2012). 
--------------------- 
Insert Figure 1 about here 
--------------------- 
 
Indeed, the idea of moving forwards through stages, which has been described as going 
from “bench to bedside”, is thoroughly ingrained in most of the existing conceptualisations of 
TR - in academia and among practitioners and policymakers (Khoury et al. 2007; Sung et al. 
2003). This stage approach to TR does not differ substantially from the classic linear stage 
process which characterises all clinical research. What makes TR approaches different is the 
explicit identification of which steps in these processes are more problematic and slow the 
progression towards application and health benefits. Thus, TR models identify a series of 
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translational chasms, gaps or blocks that need to be bridged (Woolf 2008). These chasms are 
viewed as obstacles and typically are described using what has come to be known as a “T-
terminology” (Dougherty and Heller 1994), which consists of a structured list of 
(T)ranslation gaps to be bridged. According to these models, the main objective of TR is to 
bridge these gaps so as to facilitate more rapid movement of knowledge through the 
successive steps from basic research to application. 
One of the first models adopting a T-terminology was developed by the US Institute of 
Medicine’s Clinical Research Roundtable, which identified two main gaps: T1 and T2. The 
first chasm (T1) is related to the transfer of basic discoveries into human clinical testing, the 
second, T2, refers to the dissemination and adoption of successful clinical discoveries into 
daily clinical practice. As TR research has developed, more detailed models have been 
proposed, which include more T-phases and more chasms to be bridged. Westfall et al. 
(2007) proposed a TR model beginning at T1, where knowledge coming from basic science 
moves to human clinical research through the development of Phase I and Phase II clinical 
trials. According to this model of TR the process starts at the “bench”, with fundamental 
discoveries in molecular biology, genetics and other basic sciences which may be of interest 
for understanding human health. The T2 chasm comprises the activities related to the 
translation of initial human testing results into clinical practice. Activities such as Phase III 
and Phase IV clinical trials, and observational studies and survey research, are considered to 
occur at this stage. The final gap (T3) deals with the translation into practice, and the 
dissemination of the new clinical treatment (e.g. through the development of guidelines for 
clinical practice, patients and the general population). Other models break down the 
translational continuum even further by proposing an additional final gap (T4), which 
emerges in the effort to advance towards real-world health outcomes by promoting the 
adoption of evidence-based recommendations by health practitioners (Khoury et al. 2007).  
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Some of the proponents of these linear TR models acknowledge that knowledge can flow 
also from “bedside to bench”. For instance, Marincola (2011) stresses that hypotheses tested 
in basic research experiments can be based on observational evidence from practitioners. 
Research based on clinical evidence is particularly important because it provides factual 
knowledge collected through practitioner observation (e.g. through direct contact with 
patients), which can be translated into specific hypotheses to be tested in the lab, or lead to 
ideas that open up new research avenues. However, although the bidirectional nature of TR is 
acknowledged in most TR models, the majority of TR policy initiatives pursue or are based 
implicitly on a unidirectional “bench to bedside” understanding of knowledge generation and 
application, as reflected in the terminology referring to consecutive gaps (T1, T2, T3,…) 
which need to be bridged. 
This focus on the identification of T-gaps has posed a series of challenges that have 
framed much research on TR analysis and evaluation and some problems. In analysing TR to 
find solutions to different translational gaps, the identification of these gaps and the different 
views of stakeholders about how to address them, can lead to different understandings of 
what TR is about (Van der Laan and Boenink 2012) and what specific skills scientists should 
develop to support TR (Rubio et al. 2010). Littman et al. (2007) point out that, for academics, 
TR represents (1) a channel to test whether novel ideas generated by basic science have the 
potential to translate into practical applications, (2) an opportunity to gain observational 
insights and develop novel scientific hypotheses to be tested in the lab, and (3) a means to 
gain legitimacy and improved access to research funding. However, for clinical practitioners 
such as physicians or clinical staff, TR is viewed primarily as responding to the need to 
shorten the path between scientific evidence and actual practice (Davis et al. 2003). Business 
organizations view TR as a process to accelerate the development of a new drug or therapy 
and as an opportunity to make go/no go decisions at an early stage in the biomedical 
8 
 
innovation process – potentially resulting in major savings by avoiding unproductive 
investments. Also, the fact that public organizations conduct TR is seen by industry as an 
opportunity to save on research whose returns are very uncertain (Littman et al. 2007). 
The interactive-process model of Translational Research 
Although different stakeholders may hold different views on the objectives of TR, there is a 
consensus on specific “gaps” among the succession of translational gaps. This "gap-centred" 
perspective, implicitly or explicitly sees knowledge accumulating through different stages 
from fundamental to applied research. However, some scholars have expressed concern about 
the adequacy of a linear TR model to frame analysis and develop policy strategies (Graham et 
al. 2006; Littman et al. 2007; Marincola 2011). A linear TR model builds implicitly on the 
theoretical separation between basic and applied research. Although this separation is widely 
used when talking about science and technology policy, numerous studies show that it is 
problematic. In particular, fundamental knowledge can be sought in order to solve an applied 
problem, à la Pasteur. This arguably is a different form of research, “use-inspired basic 
research” (Stokes 1997), which fits well with the TR goal of generating knowledge with an 
explicit focus on patient applications and public health benefits. However, a TR model based 
on a linear progression from basic science to health applications cannot account for the 
existence of “user-inspired basic research”. Also, a linear conceptualization of TR may clash 
with the evidence on how medical innovation processes emerge and develop in the health 
sector. The medical research process does not always proceed linearly. Rather, innovation 
scholars conceptualize it as an iterative process in which insights provided by one group of 
stakeholders spurs advancement in surrounding professional and epistemic groups (Consoli 
and Mina 2009; Hobin et al. 2012). 
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The idea that knowledge moves forwards and backwards along the unidimensional line of 
the TR continuum may partially capture the view of a dynamic relation between basic and 
applied research and the application of its results, but cannot account for the existence of a 
different type of research, involving scientists who carry out fundamental research while are 
also systematically considering potential health applications. In fact, the participants in TR 
can interact, playing different roles simultaneously. It has been argued that the progress of 
biomedical research depends increasingly on close collaboration between researchers, 
practitioners, medical institutions, patient communities and research sponsors (Meslin et al. 
2013). Here, the role of “boundary spanners”, that is, actors who facilitate communication 
across different communities, is particularly important (Lander and Atkinson-Grosjean 2011; 
Swann et al. 2007). Boundary spanners are individuals who engage in significant transactions 
with members of other communities, facilitate knowledge exchange between groups, and 
manage intergroup conflicts (Richter et al. 2006).  
From this perspective, clinical scientists working at the interface between basic scientists 
and health practitioners could play a crucial “boundary spanning” role, intermediating 
between the needs and objectives of the different actors, and conveying knowledge in a fast 
and timely manner (Kelley et al. 2012). To be effective, clinical scientists need management 
and coordination skills and knowledge of the different “languages” used by the diverse 
“epistemic cultures” of basic scientists and clinicians (Roberts et al. 2012). This is more 
easily achieved if individual researchers engage in both basic and clinical work. It has been 
suggested that clinicians working at the interface between basic scientists and the final 
beneficiaries of the research (e.g. patients) can contribute to the establishment of new 
partnering mechanisms with patients, with the objective of assessing therapies and 
performing observational studies (Kelley et al. 2012). However, the links among the diverse 
groups of actors involved in the development of new drugs and therapies can be problematic. 
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From this perspective, the main objective of TR can be redefined. Rather than focusing on 
bridging the gaps between successive stages in the TR process, the emphasis is placed on the 
roles and interactions of different actors who traditionally have fulfilled very specialized and 
compartmentalized roles. For instance, basic scientists may become involved in TR when 
conducting “user-inspired research” in close contact with, among others, clinicians and 
patients. Another form of TR can emerge when patient organizations collaborate with 
researchers to identify research problems. Clinicians can act as “boundary spanners” helping 
others make connections. There are many different ways to establish much closer working 
interactions among the different actors in the research process. Instead of seeing TR as 
addressing the problems that appear at specific points in a traditional, staged, linear research 
system, in our approach, TR addresses the separation between different groups of researchers 
and stakeholders throughout the process linking research to the development and application 
of solutions to health problems. To do so, TR focuses on processes -on how the sharing, 
exchange and acquisition of knowledge are articulated and how different actors get involved 
in this process.  
TR EVALUATION: GAPS AND LAGS VS PROXIMITIES 
Different ways of understanding the notion of TR open the way to a variety of 
translational policies and initiatives with different objectives and logics. These various 
notions are associated also with different ways of evaluating TR initiatives. In the preceding 
section we defined two main, contrasting, views of TR. Tlead to different approaches to the 
evaluation of TR.  
Gaps and lags: evaluating the translational continuum  
If TR is seen as the attempt to bridge a series of sequential gaps that hamper the 
translation of research results into socially beneficial applications, its evaluation should focus 
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on the specific gaps that TR is supposed to address rather than the whole R&D process. The 
success of a TR programme can then be defined by the extent to which it has reduced or 
bridged these gaps. The diversity of evaluation techniques that have been proposed reflects 
the different definitions of these gaps and the different indicators used to measure how well 
they have been bridged. Morris et al. reviewed 23 TR evaluation papers and concluded that 
“different studies use different measures, of different things, at different time points.” The 
authors argue further that “understanding lags first requires agreeing models, definitions and 
measures, which can be applied in practice” (Morris et al. 2011). 
This perspective assumes that the key indicator to assess TR initiatives is the time it takes 
for the different translational gaps to be bridged and, therefore, for the research to be 
translated into treatments and other health improving measures. Time lags are used also by 
Trochim et al. (2011). They develop a generic approach to TR evaluation and propose a 
flexible solution focusing on what they consider to be the final objective of TR: the reduction 
in the time needed to develop new clinical practices and drugs patients. They adopt a generic 
linear TR model to identify “markers” in the translation process and to assess the time that it 
takes for outputs to move across these markers. The identification of these markers is flexible 
and does not require a choice between one or another model of TR. There is flexibility also in 
the direction of the activity across markers, allowing for both “bench to bedside”, and 
“bedside to bench” movements. The approach suggested by Trochim et al. focuses on the 
outputs of TR, and on the time it takes for the output of a specific activity to be translated into 
a different type of output identified by another marker. In other words, this form of 
evaluation is concerned with TR outputs rather than how these outputs are achieved.  
Several TR evaluations have adopted this procedure. Even when the TR programmes 
themselves are unclear in the definition of their goals, time lag studies have become an 
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increasingly dominant approach to their evaluation. In these evaluations, the gap between the 
different research phases and the outputs they generate ceases to be an indicator of success 
and is converted into the objective of TR: shortening the time between different research 
stages becomes what TR is about. It could be argued that there is a risk of the tail of 
evaluation wagging the dog of TR. In other words, how success is measured may define the 
nature of the research objectives being pursued. Further, TR evaluations that focus on 
measuring the time lags between different research stages pay little attention to the 
standardization of such lag measurements and to understanding the factors underlying the 
measured lags (Morris et al. 2011). This presents problems for evaluation practice; for 
instance, time lags may be poorly assessed if the differences between scientific domains are 
not considered in the estimation (Contopoulos-Ioannidis et al. 2003). 
A focus on outputs and time lags has some advantages. For instance, it allows the use of 
traditional indicators, such as scientific publications, by linking them to a “marker”. This may 
be convenient since traditional indicators are easily available, but their application may 
reinforce some of the processes and practices that TR is supposed to combat. For instance, 
basic scientists can be assessed according to their published output, particularly the time it 
takes for publication to take place; however, this takes no account of how the outputs 
weregenerated, how the different research steps were defined and the roles of the different 
actors involved in the process. An understanding of TR that takes account of how the 
research and innovation processes are organized calls for a different evaluation approach. In 
the next section, we formulate an evaluation framework, which we argue is better suited to 
addressing the ways in which TR initiatives affect the research and application processes. 
Proximities: evaluating interaction processes 
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Our proposal is to focus on how TR programmes affect the ways in which research 
objectives are defined, research is conducted, and its results applied in practice. We posit that 
TR initiatives attempt to address problems in the organization and management of biomedical 
research by bridging the divide between different actors involved in the development of new 
drugs, therapies, diagnostics or public health practices. These actors include the doctors and 
patients involved in the identification and definition of therapeutic and health problems, the 
researchers defining and addressing the relevant fundamental research challenges, and the 
clinicians and doctors developing and testing solutions. These different groups belong to 
different organizations, follow different implicit and explicit rules, and respond to different 
sets of incentives and performance criteria. These conflicting logics (Sauermann and Stephan 
2013) and different epistemic cultures (Knorr-Cetina 1999) can make it difficult to align 
objectives and establish information flows. Stakeholders separated by institutional and 
organizational boundaries find it difficult to communicate needs and results. For instance, 
Ferlie et al. (2005) show that maintaining institutional separation among different medical 
professions is a major barrier to the development of medical innovations.  
Thus, TR initiatives can seek to reduce some of the divides among biomedical 
researchers, clinical doctors, general practitioners, regulators, etc. It is important to 
emphasize the networked and non-linear nature of these social interactions: for instance, 
basic research can be influenced by insights from general practitioners and regulators, 
without the mediation of clinical doctors. We would suggest that these interactions may be 
difficult to operationalize due to the various types of distance between these different groups. 
Following Boschma (2005), learning processes and knowledge exchange interactions are 
facilitated and strengthened by five forms of proximity: cognitive, social, organizational, 
institutional and spatial.  
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Cognitive proximity reflects similarities in the way people perceive, interpret, understand 
and evaluate the world (Wuyts et al. 2005). A certain degree of cognitive proximity, that is, 
the extent to which the actors share a similar knowledge base, is a prerequisite for interactive 
learning, as it facilitates effective communication and a common reference space to process 
and transfer complex information and knowledge. However, as Nooteboom (2000) and 
Boschma (2005) point out, both too much or too little cognitive proximity can be detrimental 
to innovation and learning processes. A high level of cognitive proximity can result in the 
exchange of redundant knowledge due to the similarity in the knowledge sources. Too little 
cognitive proximity can lead to the exchange of information that is not fully understood by 
the actors, rendering the communication ineffective. Thus, research on cognitive proximity 
claims that there is an optimal level of cognitive proximity for interactions between actors to 
be productive (Boschma and Frenken 2011).  
Social proximity refers to relations built on common experience, friendship and kinship, 
which can facilitate interaction and communication based on mutual trust and reciprocity. As 
social proximity between the actors increases, they know one another better communication 
becomes easier. 
Organizational proximity refers to the governance structure shaping the interactions 
between actors. High organizational proximity is often associated with a hierarchical 
structure governing the actors' interactions, while low organizational proximity is generally 
associated with a flat governance structure or arms’ length interactions among the actors.  
Institutional proximity refers to the norms, rules and values that influence how actors 
behave. Large institutional distance, promoting behaviour that responds to different, 
potentially conflicting, sets of incentives or values, may impose serious impediments to 
fruitful learning interactions among the actors. For example, the institutional distance 
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between universities and firms is considerable because their incentives and norms differ 
significantly. Institutional proximity contributes to reducing uncertainty among the actors, 
even in the absence of previous social interaction (Lagendijk and Lorentzen 2007). In the 
biomedical field, the institutional distance between different occupational and professional 
boundaries represents a major barrier to the exchange of knowledge and the spread of 
innovations (Currie and White 2012; Ferlie et al. 2005). 
Finally, geographical proximity refers to the spatial or physical distance between actors. 
This matters in knowledge dynamics because spatial co-location favours the exchange of 
knowledge that is complex or difficult to transfer (i.e. tacit knowledge) (D'Este et al. 2013; 
Frenken et al. 2012; Ponds et al. 2007). 
All these types of proximity are inter-related. Some may be complementary; others may 
act as substitutes. For instance, Harrison (1992) and Howells (2002) argue that geographical 
proximity facilitates face-to-face interactions, favouring trust-based relationships and 
knowledge exchange, suggesting a reinforcing effect of spatial proximity on social proximity. 
In contrast, some proximity dimensions may be substitutes for each other: barriers to 
knowledge exchange posed by geographic distance might be overcome if the interacting 
partners share a well-defined division of labour (i.e. organizational proximity) (Rallet and 
Torre 1999). 
The main challenge for TR programmes is developing interventions that generate a 
configuration of distances between actors that is appropriate for the specific goals of the 
programmes. Distance problems can be addressed along one or more of the dimensions 
reviewed above. For instance, initiatives can be designed to improve communication and 
understanding between patients, clinicians and researchers (addressing cognitive distance), to 
introduce coordination mechanisms across different organizations involved in the research 
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and application processes (addressing organizational distance), to align their incentives and 
norms (addressing institutional distance), or to improve trust and cohesion among actors 
(addressing social distance). In other words, different TR initiatives may be aimed at 
reducing the different distances among the actors involved in biomedical research and the 
application of its results.   
TR EVALUATION: INCREASING PROXIMITIES AND 
“PROGRAMME THEORIES” 
The first step of an alternative TR evaluation strategy is to determine the, implicit or 
explicit, “programme theory” underpinning the TR initiative under study. In other words, we 
need to define the policy goals in terms of the proximities that are to be improved and the 
process by which such improvements are expected to occur. As argued above, while the 
“gaps and lags” approach to evaluation focuses on outputs and the time it takes to progress 
from one output to another, in a proximities approach, the attention is on the research and 
knowledge utilization processes. This is in line with current proposals to focus research 
impact evaluations on the processes by which impacts are generated (Kok and Schuit 2012). 
How TR programmes pursue their goals will vary across initiatives. For example, a TR 
project may be aimed at facilitating TR by merging two laboratories. In this case, the TR 
programme logic is focused on geographical and organizational proximity. In other cases, 
laboratories (e.g. in a university and a hospital) are expected to interact, but to remain 
separate, with joint activities organized to foster knowledge exchange. In this case, the logic 
focuses on overcoming institutional distance through social and cognitive proximities. 
Drawing on two contrasting Spanish examples, the IDIBAPS centre and the CIBER networks 
initiative, we show how the dimensions of proximity can be used to describe the different 
“programme theories” of TR initiatives. 
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Collaborative centres seeking to enhance interaction via spatial 
proximity: the case of IDIBAPS 
IDIBAPS is a TR centre which is located opposite to the Clinic Hospital of Barcelona. It 
houses some 460 researchers with diverse institutional affiliations: the Clinic Hospital, the 
University of Barcelona, Spanish and Catalan research establishments (CSIC and ICREA), 
and its own staff. It provides a space for researchers with different affiliations and expertise 
to work together on different themes (e.g. biomarkers for oncology), using common facilities 
(e.g. bioinformatics, biobanks, imaging instrumentation). IDIBAPS can be described as a TR 
initiative primarily acting mainly upon spatial proximity through the co-location of 
laboratories and shared access to research facilities. This spatial proximity is expected to 
generate other forms of proximity; for instance, IDIBAPS work practices are expected to 
enhance trust and collaboration among the actors (thus increasing social proximity). 
Ultimately, these proximities should facilitate knowledge flows (increasing cognitive 
proximity) among different cognitive areas. Therefore, the evaluation of an organization like 
IDIBAPS should seek to determine whether and how expectations about interactions and 
cross-fertilization are being met.  
Collaboration networks seeking to enhance interaction via 
organizational proximity: the CIBERs 
The CIBERs were established in 2006 by the Spanish Government to promote excellence 
in biomedical research through the establishment of stable cooperative research arrangements 
which could be defined as loosely-coupled networks.4 The CIBERs were selected based on an 
open call to biomedical research groups. Applicants had to propose broad networks of 
research groups including universities, public research organizations, hospitals, clinics and 
                                                          
4 Loosely coupled networks are organizational structures that may help coordinate transactions among 
highly heterogeneous partners, providing a balance between the mechanisms of control and flexibility. Loosely 
coupled networks lie somewhere between highly hierarchical organizational structures which impose a strong 
degree of control and bureaucracy on learning-related activities, and weakly articulated governance structures 
that provide a fragile setting for building trust-based and sustainable relationships.  
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research foundations. Nine CIBER research networks5 were founded between 2006 and 2007, 
each focused on a specific pathology or disease, in line with the strategic goals of the 
Instituto Carlos III (equivalent to the US National Institutes of Health), and with the explicit 
task of conducting TR. 
Since members of the CIBERs continued to work in their own organizations, increasing 
spatial proximity was clearly not the objective of the initiative. It was aimed at coordinating, 
through the common legal and economic framework provided by the CIBER platform, 
diverse biomedical groups within universities, hospitals and public research organizations. 
The CIBER platform provides an articulated governance structure to catalyse coordinated 
actions among the actors involved in the TR process. By connecting these research groups 
through mechanisms and common practices and decision making processes agreed among all 
partners, the CIBER platform aims to increase organizational proximity among a group of 
heterogeneous research actors.  
Although the groups belonging to a CIBER are only “loosely coupled” we can expect 
that, by setting some basic conditions for the creation of common rules and shared 
expectations, the CIBERs may provide the means to generate social proximity and through it 
increase cognitive proximity. In other words, the CIBER networks can be understood as an 
organizational arrangement, aimed primarily at increasing the organizational proximity 
among the actors (basic researchers, doctors, patient groups), who tend to be distant in all 
dimensions. This greater organizational proximity should enhance social proximity, which 
should facilitate cognitive flows. 
                                                          
5 Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Epidemiology and Public Health 
(CIBER-ESP), Obesity and Nutrition (CIBER-OBN), Hepatic and Digestive Diseases (CIBER-EHD), 
Neurodegenerative Diseases (CIBER-NED), Respiratory Diseases (CIBER-ES), Rare Diseases (CIBER-ER), 
Mental Health (CIBER-SAM) and Diabetes and Metabolic Associated Diseases (CIBER-DEM). 
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ANALYSING PROXIMITIES AND THE IMPLICATIONS FOR 
EVALUATING TRANSLATIONAL RESEARCH 
The need for a programme theory 
TR addresses a problem that has organizational, social and cognitive roots: different 
communities with different practices and values are involved in a process that is complex and 
difficult (Currie and White 2012). The above two cases illustrate how two different 
initiatives, both labelled translational, have taken different approaches and implicitly draw on 
different programme theories. The forms of collaboration and interaction that we can expect 
from these initiatives are very different, and we suggest that when evaluating them we should 
aim at understanding these differences. We are interested in investigating how research 
objectives and projects are designed, how the research is conducted, and how the application 
of research results is and carried out. In other words, we need to understand the variety of the 
processes involved in TR initiatives.  
We argue that a process-based approach to evaluation has advantages over an evaluation 
focusing on outputs. First, focusing on outputs provides no information on why an output has 
or has not been generated according to the initial, implicit or explicit, expectations of 
stakeholders. Second, existing practices could be relabelled “translational” if TR policies and 
their evaluation were concerned only with the generation of outputs and their identification. 
In the case of TR, where there is ambiguity about what differentiates it from other research 
forms, understanding how interventions operate in practice and what processes they trigger is 
particularly important. If TR initiatives are to be transformative, they must implement 
changes in the way research and the development of clinical practices and therapies are 
conducted. This calls for an approach that goes beyond “linear evaluation” of TR. It requires 
an evaluation approach that focuses on these processes. Third, evaluation frameworks are not 
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neutral in relation to the objectives of an initiative. The way in which a project is evaluated 
will affect how it is conducted and how its performers conceive their objectives. Focusing on 
specific outputs can implicitly suggest an intervention rationale that is not concerned with the 
organization of the research or how specific “translational gaps” are addressed.  
The proximities framework we have proposed helps to focus attention on the way the 
research is conducted and the specific aspects that the initiative is intended to address. These 
aspects may sometimes be made explicit in the definition of the intervention, but they may 
also only be implied in relation to how the initiative is implemented. In this latter case, the 
framework could be used to explore and develop a “programme theory” for a TR initiative; in 
other words, help policymakers to reflect on and explore the initiative's rationale. The cases 
described show how the framework can  be used to describe both the goals of a TR initiative 
and how these goals can be achieved.  
In adopting this approach, we are proposing that the immediate goal of a TR initiative is 
to address the problem of the distances separating the different groups involved in medical 
research. The “translational gaps” are due to excessive distance in one or more significant 
dimensions. The groups involved in the translational process have cognitive differences, are 
institutionally separate and, therefore, follow different rules, are faced with different types of 
incentives, and often are geographically dispersed. The definition of an initiative and its 
evaluation must be flexible and allow for the fact that too much proximity is not always 
desirable. For instance, too large a cognitive distance can be problematic, but so can too 
much cognitive overlap; cognitive proximity is positive only up to a certain level. A specific 
programme theory must reflect this problem of balance, and the interpretation of evaluation 




The programme theory of a TR initiative should define expectations about whether and 
how changes in proximity in one or more dimensions caused by the intervention, will trigger 
shifts in the other dimensions, and the effects of these changes on the development and 
application of beneficial goods and services. These effects will be mediated by changes to the 
way research is carried out. Increased proximity can result in increased collaboration among 
the groups involved in the various tasks that constitute the TR process (the definition of 
fundamental and clinical research objectives, research, and the application of its results). We 
can expect changes in proximity to generate new interactions across groups, for instance, 
between research performers and the diverse users and beneficiaries of the research results, 
where knowledge moves back and forth along various channels, and within networks, rather 
than along a linear bedside to bench continuum.  
We can identify other building blocks of a TR programme theory. An intermediate 
outcome of increased proximities may be the generation of complex interactions among the 
different groups involved in the TR process. Although this may vary across initiatives, it is 
important to take into account the broad variety of potential stakeholders: basic researchers, 
clinical researchers, technologists, practitioners (doctors, nurses, etc.) public health and 
private industry managers, and patients. The ways in which stakeholder groups interact can 
be traced and analysed using instruments developed for the evaluation of the socio-economic 
impact of research, such as those developed by the EU-funded SIAMPI project (Molas-
Gallart and Tang 2011; Spaapen and van Drooge 2011), which focuses on the processes of 
collaboration that can be linked to an initiative.  




This paper has argued that a different approach to the evaluation of TR is both possible 
and desirable and has shown that it will rely on programme theories which will need to be 
developed for each different TR initiative. The next step will be to operationalize the 
approach. While an output-based gaps and lags evaluation provides easily measureable and 
potentially comparable results, a proximities approach to evaluation will yield a description 
of the contextual conditions in which the initiative was implemented and its effects on the 
relevant processes. Narratives built on qualitative research techniques could describe how the 
different proximities evolve throughout an intervention. The narratives could be accompanied 
by quantitative indicators; there are numerous examples from the innovation studies, 
economic geography and management literatures of attempts to measure different proximity 
dimensions. The main approaches to developing proximity measures draw heavily on two 
alternative sources: primary data mainly from surveys and fieldwork research, and secondary 
data relying mainly on bibliographic and patent information. Cognitive proximity has been 
measured as the degree of overlap among the knowledge bases of potentially interacting 
actors. This overlap can be captured at the individual level by analysing the similarity 
between scientists’ publications or patents profiles (Kotha et al. 2013). The cognitive distance 
between actors can be captured by focusing on the patent subcategories in which their 
discoveries are classified (Tzabbar 2009). Finally, science maps offer a visualization of the 
overlap between actors across scientific fields (Rafols et al. 2010) or patent categories (Kay 
et al. 2014). Geographical proximity can be operationalized by measuring the physical 
distance between the interacting partners, based on their physical addresses (Laursen et al. 
2011). Geographical information based on postcodes allows the calculation of the "great 
circle" distances between any two partners, while relative measures of distance, such as travel 
times between any two location points, have also been used (Ejermo and Karlsson 2006). 
Institutional proximity refers to whether actors belong to similar or distinct types of 
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institutions (e.g., universities, hospitals, public research organizations, etc.). Bibliometric 
analysis may be useful to explore actors affiliated to more than one institution (e.g. a hospital 
and a university). Organizational proximity is often measured by whether actors belong to the 
same organizational structure and, thus, answer to the same authority. A more detailed 
approximation of organizational proximity can be obtained by measuring the degree to which 
the organization is characterized by a flatter or more vertical chain of command (Ponds et al. 
2007), and the relative position of actors in these "hierarchies". Social proximity can be 
proxied by the extent to which actors have interacted in the past, for instance, via co-
authorship or co-inventorship, and the duration of such linkages (McFayden et al. 2009). 
Softer measures based on social network research can be captured through surveys enquiring 
about the extent to which actors have developed strong ties with each other, reflecting a 
relationship of kinship, trust and reciprocity (McFayden and Cannella 2004). 
Thus, there is a variety of techniques that can be adapted for use in evaluation research. 
Use of a proximities framework does not determine the research techniques to be employed; 
these need to fit the specific circumstances of the individual initiative being assessed. The 
activities supported by a TR initiative will be different, be implemented in different contexts 
and will have different targets and objectives. For instance, the research techniques applied to 
an initiative that focuses mainly on cognitive issues, will be different from those applied to 
one that addresses institutional differences. 
Since the adequacy of a specific research technique will depend on the specific TR 
evaluation problem and its context, it follows that the outputs of TR evaluations will not and 
should not be directly comparable. Calls for an approach based on a single set of research 
techniques, yielding measurable and comparable indicators of TR “output”, from our 
perspective, are out of place. An evaluation approach that focuses on processes will seek to 
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provide detailed information on the effects of an initiative starting at the level of those groups 
directly involved in it. However, the way that this information is shaped, and the indicators 
on which it is based will depend on the type of initiative, its objectives, and the types of 
proximities the programme is designed to address. 
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